Respironics® Launches the REMstar® Pro M Series Sleep System

Murrysville, PA - June 19, 2006

Respironics, Inc. (NASDAQ/NMS Symbol: RESP) recently released its REMstar Pro M Series, the second model in its M Series line of sleep systems with C-Flex™. The REMstar M Series is the only complete line of sleep therapy systems that provides proven patient comfort and ease of use in a sleek, modern design. The products are designed for the treatment of adults who have obstructive sleep apnea.

With its small size, three easy-to-use primary control buttons and more lifestyle-oriented design, the REMstar M Series is targeted at improving the patient's acceptance to therapy. Comfort features such as ramp and integrated humidification are incorporated into the design. The optional ramp feature reduces the air pressure when a patient is trying to fall asleep and then gradually increases (or ramps) the pressure until the device reaches the patient's prescription setting. For patients using humidification, a less obtrusive humidifier chamber adds to the sleek appearance of the platform, and is easier to remove and fill. REMstar Pro is also able to automatically compensate for different altitudes.

To help make therapy more comfortable, the REMstar Pro M Series features C-Flex technology. C-Flex tracks the patient's breathing and lowers the amount of pressure delivered during exhalation. With three settings, patients have the ability to select the level of pressure relief that's right for them, without altering the benefits of prescribed therapy. C-Flex helps to make exhaling against the CPAP pressure easier, providing a more comfortable treatment and ultimately increasing the likelihood of compliance.

In a recent study involving both CPAP and C-Flex users, remarkably, after three months, patients using

C-Flex technology used their therapy an average of one-hour and 42-minutes longer per night than patients on traditional CPAP. In a separate study, patients using C-Flex had a significantly greater satisfaction with treatment comfort and interface comfort, and greater overall satisfaction with therapy at six months.

The REMstar Pro M Series has also been designed with an improved data logging system to make data management more efficient. Reports are easily accessible to read and share among physicians/clinicians and homecare providers. Equipped with an Encore ® Pro SmartCard ® accessory module, the REMstar Pro records and reports advanced compliance information such as apnea/hypopnea index, snoring, and leaks. A self-management feature allows the proactive user to assess the therapeutic benefit of treatment.

Says Jeff Maglin , Global Product Manager, Sleep Therapy, "The REMstar Pro M Series fills the need for an enhanced compliance-tracking device packaged with true consumer appeal. The combination of advanced technology for providers and ease of use for patients helps to improve acceptance, comfort and results for its users."

About Respironics

Respironics' Sleep and Home Respiratory Group is recognized worldwide for its continuous stream of medical innovations and advancements in the management of sleep disorders and chronic respiratory problems. The Group integrates state-of-the-art technology in diagnostics, therapy and monitoring with strategic problems to help health care providers, sleep centers and pediatric units care for patients efficiently and cost-effectively.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,600 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.